We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.53B
1-Year Est. Return 154.61%
This Fund
S&P 500
This Quarter Est. Return
+5.53%
1 Year Est. Return
+154.61%
3 Year Est. Return
+564.07%
5 Year Est. Return
+985.88%
10 Year Est. Return
–
AUM
$2.09B
AUM Growth
+$76.9M
Cap. Flow
-$52.7M
Cap. Flow %
-2.52%
Top 10 Hldgs %
44.54%
Holding
114
New
28
Increased
33
Reduced
17
Closed
24

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$38.4M
2
RVMD icon
Revolution Medicines
RVMD
+$30.3M
3
ROIV icon
Roivant Sciences
ROIV
+$29.5M
4
BSX icon
Boston Scientific
BSX
+$26M
5
MRK icon
Merck
MRK
+$20.2M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$64.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$37.9M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$31.2M
4
PEN icon
Penumbra
PEN
+$31.1M
5
TFX icon
Teleflex
TFX
+$30.5M

Sector Composition

Rank Sector Weight
1 Healthcare 90.39%
2 Miscellaneous 9.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVMN
76
Evommune Inc
EVMN
$480M
$5.17M 0.25%
225,000
+100,000
+80% +$2.26M
ACHC icon
77
Acadia Healthcare
ACHC
$2.66B
$4.68M 0.22%
+200,000
New +$3.62M
ZBH icon
78
Zimmer Biomet
ZBH
$19.2B
$4.52M 0.22%
+50,000
New +$4.59M
FBRX icon
79
Forte Biosciences
FBRX
$3.88M 0.19%
+150,000
New +$4.32M
LBRX
80
LB Pharmaceuticals
LBRX
$1.54B
$3.7M 0.18%
150,000
+50,000
+50% +$1.15M
SVRA icon
81
Savara
SVRA
$1.08B
$3.28M 0.16%
+600,000
New +$3.34M
RLMD icon
82
Relmada Therapeutics
RLMD
$462M
$3.13M 0.15%
+450,000
New +$2.13M
IMCR icon
83
Immunocore
IMCR
$1.89B
$3.02M 0.14%
+100,000
New +$3.24M
MAZE
84
Maze Therapeutics
MAZE
$1.52B
$2.98M 0.14%
100,000
– –
TENX icon
85
Tenax Therapeutics
TENX
$79.7M
$2.67M 0.13%
167,000
– –
IKT icon
86
Inhibikase Therapeutics
IKT
$336M
$2.27M 0.11%
1,350,000
-400,000
-23% -$710K
OLMA icon
87
Olema Pharmaceuticals
OLMA
$899M
$2.24M 0.11%
+150,000
New +$3.34M
IVA
88
Inventiva
IVA
$1.11B
$2.22M 0.11%
+400,000
New +$2.44M
SION
89
Sionna Therapeutics
SION
$265M
$2M 0.1%
+50,000
New +$1.91M
UNCY icon
90
Unicycive Therapeutics
UNCY
$147M
$1.48M 0.07%
+225,000
New +$1.47M
ACLX
91
DELISTED
Arcellx
ACLX
– –
-200,000
Closed -$13M
ALNY icon
92
Alnylam Pharmaceuticals
ALNY
$31.7B
– –
-60,000
Closed -$23.9M
APLS
93
DELISTED
Apellis Pharmaceuticals
APLS
– –
-200,000
Closed -$5.02M
BCRX icon
94
BioCryst Pharmaceuticals
BCRX
$2.51B
– –
-200,000
Closed -$1.56M
BRKR icon
95
Bruker
BRKR
$8.7B
– –
-125,000
Closed -$5.89M
CRL icon
96
Charles River Laboratories
CRL
$13.9B
– –
-45,000
Closed -$8.98M
DOCS icon
97
Doximity
DOCS
$4.76B
– –
-400,000
Closed -$17.7M
EHC icon
98
Encompass Health
EHC
$11.9B
– –
-100,000
Closed -$10.6M
EYPT icon
99
EyePoint Inc
EYPT
$386M
– –
-200,000
Closed -$3.65M
GOSS icon
100
Gossamer Bio
GOSS
$83.2M
– –
-1,000,000
Closed -$3.1M
1 2 3
4
5

Similar funds

VWA
Visionary Wealth Advisors O'fallon, Illinois $2.53B AUM 24.4% 1-Year Est. Return
PVI
Pine Valley Investments Marlton, New Jersey $2.53B AUM 36.18% 1-Year Est. Return
AIM
Acropolis Investment Management St. Louis, Missouri $2.54B AUM 18.96% 1-Year Est. Return
QT
Quantbot Technologies New York $2.54B AUM 22.25% 1-Year Est. Return
LMIM
Lockheed Martin Investment Management Bethesda, Maryland $2.53B AUM 37.62% 1-Year Est. Return
ST
Sageworth Trust Lancaster, Pennsylvania $2.54B AUM 23.56% 1-Year Est. Return
NSAM
North Star Asset Management Neenah, Wisconsin $2.54B AUM 17.62% 1-Year Est. Return
IFA
Index Fund Advisors Irvine, California $2.52B AUM 26.26% 1-Year Est. Return

Integral Health Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Integral Health Asset Management held 114 positions worth $2.09B, up 3.8% from $2.01B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Integral Health Asset Management's Q1 2026 filing shows 28 new, 33 increased, 17 reduced and 24 closed positions. Its largest new stake was Alumis Inc: 800,000 shares worth $17.6M. The largest sale was Medtronic, an estimated $64.8M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

  • Integral Health Asset Management's largest Q1 2026 buy was Alumis Inc: 800,000 shares worth $17.6M.
  • Integral Health Asset Management added most to Insmed in Q1 2026, an estimated $38.4M increase.
  • Integral Health Asset Management's biggest Q1 2026 reduction was Intuitive Surgical, cutting an estimated $37.9M.
  • Integral Health Asset Management fully exited Medtronic in Q1 2026, selling an estimated $64.8M.
  • Integral Health Asset Management's ten largest holdings make up 45% of its $2.09B portfolio in Q1 2026.
  • Integral Health Asset Management opened 28 new positions and closed 24 in Q1 2026.
  • Integral Health Asset Management's portfolio value rose 3.8% quarter-over-quarter to $2.09B.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.